Related Experiment Video

Updated: Mar 29, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.9K

[The genetic variability of complement system in pathogenesis of age-related macular degeneration]

Agnieszka Kubicka-Trząska, Izabella Karska-Basta, Sylwia Dziedzina

    Klinika Oczna
    |December 8, 2015
    PubMed

    Insights

    Genetic factors, particularly complement pathway gene variants like CFH and C3, are strongly linked to age-related macular degeneration (AMD). Understanding these genetic markers is crucial for identifying AMD subtypes and improving treatments.

    Area of Science:

    • Ophthalmology
    • Genetics
    • Immunology

    Background:

    • Age-related macular degeneration (AMD) is a primary cause of irreversible vision loss in individuals over 50.
    • AMD pathogenesis involves complex environmental, immune, and genetic factors.
    • The complement pathway is increasingly implicated in AMD development.

    Purpose of the Study:

    • To review the association between complement pathway gene variants and AMD.
    • To highlight the significance of genetic variations in different ethnic groups.
    • To emphasize the need for phenotyping to identify AMD subtypes.

    Main Methods:

    • Literature review of genetic association studies.
    • Analysis of complement pathway genes including CFH, CFB, C2, and C3.
    • Examination of specific polymorphisms and their prevalence in various populations.

    Main Results:

    • The CFH gene variant Y402H (rs1061170) shows a strong association with AMD in Caucasians.
    • C3 gene polymorphism Arg102Gly (rs2230199) is a high-risk marker for AMD.
    • Protective haplotypes in C2 and BF genes were observed in Caucasian populations.

    Conclusions:

    • Genetic variations in complement pathway genes are significant risk factors for AMD.
    • Identifying AMD subtypes based on genetic profiles and environmental factors is essential.
    • Further research can enhance AMD prevention and therapeutic strategies.

    More Related Videos

    Enrichment of Bruch's Membrane from Human Donor Eyes10:22

    Enrichment of Bruch's Membrane from Human Donor Eyes

    Published on: November 15, 2015

    12.7K
    Efficient Dissection and Culture of Primary Mouse Retinal Pigment Epithelial Cells08:33

    Efficient Dissection and Culture of Primary Mouse Retinal Pigment Epithelial Cells

    Published on: February 10, 2021

    7.4K

    Related Concept Videos

    Complement System01:27

    Complement System

    The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
    12.6K
    iPS Cell Differentiation01:22

    iPS Cell Differentiation

    The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
    3.3K
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    109